{
  "abstract": "Background and Aims The United States Food and Drug Administration recently approved Suzetrigine, a first-in-class, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. The aim of the study was to characterize initial prescribing practices of Suzetrigine in a high-volume outpatient pain management clinic in New York.Methods After IRB approval for an institutional electronic-health record-based registry capturing new patient visits with qualifying diagnoses at the outpatient pain management clinics at Hospital for Special Surgery, patients who were prescribed Suzetrigine between February 1st, 2025 to May 16th, 2025 were identified with the Epic SlicerDicer tool. Patient characteristics, primary diagnoses, Suzetrigine dosing regimens, and self-reported efficacy - where available - were extracted.Results A total of 18 patients received a prescription for Suzetrigine during the study period ( figure 1 & table 1). Patients with chronic pain were prescribed Suzetrigine to manage acute post-procedural pain, complex regional pain syndrome two months following knee arthroscopy, acute pain from re-injury, or off-label for acute flares of existing conditions such as erythromelalgia, myofascial pain, or sciatica that are not responding to current medications and treatments. Overall, available data indicate that three patients explicitly requested a prescription of Suzetrigine, one patient did not fill the prescription due to cost and not knowing it would work, and two patients received a one-month supply, one of which received two refills. Four patients did not experience any pain relief, and one patient experienced significant relief with addition of Suzetrigine (NRS 9 to 6).Abstract EP132 Figure 1Number of registry patient prescribed suzetrigineAbstract EP132 Table 1Patient characteristics and clinical indications for a suzetrigine prescriptionConclusions Suzetrigine was prescribed on and off-label for a variety of painful conditions and in patients older than 65 years old. Most received a prescription for 2 weeks. Additional trials and pharmacoepidemiological studies are needed to evaluate Suzetrigine’s long-term safety and efficacy in well-defined populations.",
  "authors": [
    {
      "affiliations": [
        "Pain Prevention Research Center, Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery, New York, USA",
        "Department of Anesthesiology, Weill Cornell Medicine, New York, USA"
      ],
      "name": "Alexandra Sideris"
    },
    {
      "affiliations": [
        "Department of Anesthesiology, Weill Cornell Medicine, New York, USA",
        "Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery, New York, USA"
      ],
      "name": "Daniel Richman"
    },
    {
      "affiliations": [
        "Pain Prevention Research Center, Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery, New York, USA",
        "Department of Anesthesiology, Weill Cornell Medicine, New York, USA"
      ],
      "name": "Anuj Malhotra"
    },
    {
      "affiliations": [
        "Department of Anesthesiology, Weill Cornell Medicine, New York, USA",
        "Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery, New York, USA"
      ],
      "name": "Seth Waldman"
    },
    {
      "affiliations": [
        "Pain Prevention Research Center, Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery, New York, USA",
        "Department of Anesthesiology, Weill Cornell Medicine, New York, USA"
      ],
      "name": "Faye Rim"
    },
    {
      "affiliations": [
        "Pain Prevention Research Center, Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery, New York, USA"
      ],
      "name": "Tina Chen"
    },
    {
      "affiliations": [
        "Pain Prevention Research Center, Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery, New York, USA"
      ],
      "name": "William Chan"
    },
    {
      "affiliations": [
        "Department of Anesthesiology, Weill Cornell Medicine, New York, USA",
        "Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery, New York, USA"
      ],
      "name": "Semih Gungor"
    }
  ],
  "title": "EP132 Initial prescribing practices of suzetrigine for patients with chronic pain",
  "uid": "667d6d98-0fcc-571d-9aed-cc1101070323"
}